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Time-varying Comparison of All-cause Mortality
After Liver Transplantation Between Recipients
With and Without Hepatocellular Carcinoma: A
Population-based Cohort Study Using the United
Kingdom Liver Transplant Registry
Jyoti Sehjal, MSc,1 Linda D. Sharples, PhD,1 Ruth H. Keogh, DPhil,1 Kate Walker, PhD,2
Andreas Prachalias, MD,3 Nigel Heaton, FRCS,3 Tommy Ivanics, MD, MPH,4,5,6
Jan van der Meulen, PhD,2 and David Wallace, PhD2,3

Background. Accurately identifying time-varying differences in the hazard of all-cause mortality after liver transplantation
(LT) between recipients with and without hepatocellular carcinoma (HCC) may inform patient selection and organ allocation
policies as well as post-LT surveillance protocols. Methods. A UK population-based study was carried out using 9586
LT recipients. The time-varying association between HCC and post-LT all-cause mortality was estimated using an adjusted
flexible parametric model (FPM) and expressed as hazard ratios (HRs). Differences in this association by transplant year were
then investigated. Non–cancer-specific mortality was compared between HCC and non-HCC recipients using an adjusted
subdistribution hazard model. Results. The HR comparing HCC recipients with non-HCC recipients was below one immediately after LT (1-mo HR = 0.76; 95% confidence interval [CI], 0.59-0.99; P = 0.044). The HR then increased sharply to
a maximum at 1.3 y (HR = 2.07; 95% CI, 1.70-2.52; P < 0.001) before decreasing. The hazard of death was significantly
higher in HCC recipients than in non-HCC recipients between 4 mo and 7.4 y post-LT. There were no notable differences
in the association between HCC and the post-LT hazard of death by transplant year. The estimated non–cancer-specific
subdistribution HR for HCC was 0.93 (95% CI, 0.80-1.09; P = 0.390) and not found to vary over time. Conclusion. FPMs
can provide a more precise comparison of post-LT hazards of mortality between HCC and non-HCC patients. The results
provide further evidence that some HCC patients have extra-hepatic spread at the time of LT, which has implications for
optimal post-LT surveillance protocols.

(Transplantation 2022;00: 00–00).
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INTRODUCTION
Liver transplantation (LT) has become the preferred curative treatment option for patients with early stage hepatocellular carcinoma (HCC).1 The 5-y post-LT survival in
HCC recipients whose preoperative tumor characteristics
are within the Milan criteria (a single tumor with diameter
≤5 cm or at most three nodules each with diameter ≤3 cm
with no angioinvasion or extra-hepatic involvement) is at
least 70%.2
The long-term immunosuppressive management of LT
recipients requires a prolonged and careful balancing of
the risk of graft rejection and infection.3 The post-LT hazard of death has a “bathtub” shape in that there is initially
a high hazard of death from the surgery, primary nonfunction, and infection, followed by a period of low hazard,
before the hazard increases again due to other issues, such
as comorbidities and cancer recurrence.4
In this context, HCC is likely to have a greater impact
on some recorded causes of death than others, so one cannot assume that the hazards of death for HCC and nonHCC recipients will be the same throughout the post-LT
period.5 Traditional proportional hazards models used to
analyze survival data assume that the ratio of hazards for
two groups is constant over time. This may not be appropriate, potentially resulting in a biased estimate of the
hazard ratio (HR) for HCC and inaccurate predictions of
(particularly long-term) survival.
Allowing for a time-varying association between HCC
and the hazard of post-LT mortality can help clinicians determine the times at which HCC recipients have a higher hazard of death compared with non-HCC recipients. Adding
time-varying interactions between HCC and transplant year
also allows for the comparison of the association between
HCC and the hazard of post-LT mortality over time to ascertain whether the significant changes in LT management has
improved outcomes in these recipients. Investigating causespecific mortality may help policymakers to better understand
when recurrence following LT is most likely to be detectable
and plan the surveillance of such patients accordingly.
The aims of this study were 2-fold. First, after adjusting
for donor and recipient confounders, the hazard of postLT all-cause mortality was compared between HCC and
non-HCC recipients to identify the period for which the
relative hazard of death was highest. Time-varying interactions between HCC and transplant year were then used to
assess whether there were any differences in the association
between HCC and the post-LT hazard of death between
1997 and 2016. Second, the association between HCC and
non–cancer-specific mortality was estimated to provide further evidence that the increased relative hazard of death in
HCC recipients was primarily due to post-LT HCC occurrence. To achieve these aims, a flexible parametric survival
model for all-cause mortality and a subdistribution hazard
model for non–cancer-specific mortality were applied to a
dataset containing information on 9586 LT recipients from
the United Kingdom Liver Transplant Registry (UKLTR).6,7
MATERIALS AND METHODS
The United Kingdom Liver Transplant Registry

The UKLTR contains data from a population-based
cohort managed by the National Health Service Blood
and Transplant (NHSBT). Data were extracted for all

11 926 adult elective transplants performed in the United
Kingdom between January 1, 1995‚ and December 31,
2016. Patients attended regular post-LT examinations and
were followed up until death or October 29, 2017, the
date of data extraction.6
Study Population

The study population comprised recipients aged ≥17
(the age at which liver transplant recipients are considered to require adult-level treatment in the UK) who
received their first elective orthotopic liver-only transplant in the UK between January 1, 1997‚ and December
31, 2016. Exclusion criteria were LT for acute liver
failure, auxiliary transplant, primary liver cancer types
other than HCC, domino or a living-donor transplant, or
missing survival data.8 Recipients with data entry errors
were also excluded, for example, if the cause of death
was reported but not the date of death or if their reported
transplant date was earlier than the date of liver donation
(Figure 1).
Data

The endpoint was recipient death, and survival time was
recorded in days from LT. Recipients were censored if they
were lost to follow-up or if they were alive at their last
examination before data extraction.
Primary causes of death were grouped into HCC-specific,
other cancers (including lymphoid and nonlymphoid
malignancies possibly induced by immunosuppression),
and non–cancer-specific causes using clinical knowledge
(Table S1, SDC, http://links.lww.com/TP/C507).
The causal association between HCC and mortality
was assessed by adjusting for previously established confounders (Table S2, SDC, http://links.lww.com/TP/C507).7
Most confounders were measured objectively before LT.
Recipient confounders that were adjusted for are age, sex,
body mass index (BMI), ethnicity, previous abdominal
surgery, ascites, renal support status, variceal bleed status,
anti-hepatitis C virus (HCV) test result, hospital in-patient
status, transplant year, encephalopathy, international normalized ratio, serum bilirubin, serum creatinine, serum
sodium, serum albumin, and serum potassium. Donor confounders that were adjusted for are age, sex, BMI, cause
of death, donor type, graft type, cold ischemia time, and
organ appearance.
Liver disease diagnoses were grouped using a classification proposed by Roberts et al (Table S3, SDC, http://
links.lww.com/TP/C507).9 Recipients were assigned the
diagnosis that would have most likely affected their postLT prognosis using a disease hierarchy based on clinical
knowledge.9,10 HCC diagnosis was derived directly from
liver disease etiology.
Statistical Analysis

Descriptive Analysis
Categorical and binary variables were tabulated to give
frequencies and continuous variables were summarized
by their mean, SD, median, and range. Histograms were
produced for continuous variables to identify outlying and
implausible values compared with published literature.10,11
Implausible or outlying values were replaced as missing
(Table S2, SDC, http://links.lww.com/TP/C507).

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc
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FIGURE 1. Flowchart of recipient numbers throughout the analysis. NHSBT, National Health Service Blood and Transplant; UK, United
Kingdom.

Comparisons of other covariates between HCC and
non-HCC recipients used chi-squared tests or Fisher’s
exact tests for categorical variables, ordinal logistic regression for ordered categorical variables (eg, recipient lifestyle
activity score), and Student t-tests or Wilcoxon–Mann–
Whitney tests for normally and nonnormally distributed
continuous variables, respectively. Patients transplanted
for non-HCC indications who were reported to have died
from HCC occurrence were analyzed on an intention-totreat basis and remained in the non-HCC cohort.
Kaplan–Meier survival curves were produced by levels of HCC and the other covariates to explore their univariable associations with recipient survival. Univariable
log-rank tests were used to formally test for differences
between the survival curves by levels of each variable.
Unadjusted cumulative incidence functions for each
cause of death were produced by HCC diagnosis. They

correspond to the marginal probability of dying from a
certain cause.

Development of Multivariable Models
Although the main analysis used a flexible parametric
model (FPM), a multivariable Cox proportional hazards
model was used to determine how the adjustment variables were entered in the models. The scaled Schoenfeld test
and residuals were used to assess the proportional hazards
assumption.12,13 The functional form of the linear predictor, conditional on the other variables, was investigated
using Martingale residuals.14 Interactions between HCC
and each confounder were assessed individually and kept
in the model if the P value was <0.05. Continuous covariates (except for transplant year) were centered around
their median values and scaled for modeling. Stratified
and Cox predicted survival curves at baseline values of the

TABLE 1.

UKELD score

INR

57.1 (8.2)
58 (17, 74)
1525 (81.2)
352 (18.8)
1535 (81.5)
349 (18.5)
27.6 (4.6)
27.1 (15.6, 45.9)
275 (14.6)
321 (17.0)
561 (29.8)
728 (38.6)
1651 (87.7)
231 (12.3)
1301 (69.1)
582 (30.9)
1878 (99.7)
5 (0.3)
1804 (96.0)
76 (4.0)
1543 (82.4)
330 (17.6)
1623 (87.3)
237 (12.7)
215 (11.5)
740 (39.7)
800 (42.9)
93 (5.0)
16 (0.9)
984 (55.4)
793 (44.6)
1784 (94.7)
99 (5.3)
1.4 (0.7)
1.2 (0.7, 13.1)
51.2 (4.9)
50 (39, 72)

51.0 (11.4)
53 (17, 74)
4619 (60.8)
2979 (39.2)
6756 (87.7)
944 (12.3)
26.5 (5.1)
25.8 (11.6, 50.7)
1842 (23.9)
1793 (23.3)
1727 (22.4)
2339 (30.4)
6523 (85.0)
1154 (15.0)
3059 (39.9)
4611 (60.1)
7646 (99.4)
47 (0.6)
7308 (95.0)
382 (5.0)
5251 (68.8)
2386 (31.2)
5426 (71.0)
2211 (29.0)
253 (3.3)
1963 (25.7)
4139 (54.2)
1057 (13.8)
228 (3.0)
6056 (84.7)
1097 (15.3)
6489 (84.3)
1207 (15.7)
1.6 (0.9)
1.4 (0.7, 18.6)
55.9 (5.5)
55 (40, 86)

Non-HCC recipients (N = 7701)

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.092

0.079

<0.001

0.002

<0.001

<0.001

<0.001

<0.001

<0.001

P
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In-patient status

Anti-HCV test result

Lifestyle activity score

Encephalopathy

Variceal bleed status

Renal support status

Ventilation status

Ascites

Previous abdominal surgery

Transplant year

BMI at registration, kg/m2

Mean (SD)
Median (range)
Male, n (%)
Female, n (%)
White, n (%)
Non-White, n (%)
Mean (SD)
Median (range)
1997–2001, n (%)
2002–2006, n (%)
2007–2011, n (%)
2012–2016, n (%)
No previous surgery, n (%)
Previous surgery, n (%)
No ascites, n (%)
Ascites, n (%)
Not ventilated, n (%)
Ventilated, n (%)
Not required, n (%)
Required, n (%)
No variceal bleed, n (%)
Variceal bleed n, (%)
Not encephalopathic, n (%)
Encephalopathic, n (%)
Normal, n (%)
Restricted, n (%)
Self-care, n (%)
Confined, n (%)
Reliant, n (%)
Negative, n (%)
Positive, n (%)
Out-patient, n (%)
In-patient, n (%)
Mean (SD)
Median (range)
Mean (SD)
Median (range)

HCC recipients (N = 1885)

Transplantation
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Serum albumin, g/L

Serum sodium, mmol/L

Serum potassium, mmol/L

BMI, body mass index; CI, confidence interval; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; INR, international normalized ratio; LT, liver transplantation; UKELD, United Kingdom Model for End-Stage Liver Disease.

<0.001

<0.001

<0.001

<0.001
Serum bilirubin, µmol/L

Serum creatinine, µmol/L

Mean (SD)
Median (range)
Mean (SD)
Median (range)
Mean (SD)
Median (range)
Mean (SD)
Median (range)
Mean (SD)
Median (range)

85.0 (27.1)
80 (30, 365)
36.3 (47.6)
23 (2, 736)
4.2 (0.5)
4.1 (2.9, 6.9)
138.2 (4.4)
139 (119, 158)
33.5 (7.4)
34 (10, 52)

91.5 (45.6)
83 (16, 915)
100.9 (130.4)
55 (2, 1151)
4.2 (0.6)
4.2 (2.1, 7.6)
136.1 (5.0)
137 (112, 160)
30.6 (6.6)
30 (8, 56)

<0.001

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc
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covariates were used to show that assuming proportional
hazards for HCC was not appropriate.
Martingale residual plots showed that including recipient age-squared and BMI-squared improved the models.
Likewise, serum bilirubin and serum creatinine were logtransformed for subsequent modeling. All other continuous variables were modeled linearly.
To produce a smooth curve for the association between
HCC and all-cause mortality, an FPM with a time-varying
effect of HCC was used.15 The FPM uses a series of polynomial functions, joined together at specific points termed
“knots,” to analyze survival data.16 These polynomials
better describe how the baseline hazard changes over time
in complex clinical settings, such as that observed post-LT,
compared with other parametric models.
Akaike and Bayesian information criteria were used to
determine the number of knots.16 Knots were positioned at
centiles of the distribution of the log event times to ensure
an equal number of events in each interval.16,17 The FPM
was then extended to include a time-varying interaction
between HCC and transplant year.
Fine and Gray’s methods were used to obtain a subdistribution hazard ratio (SHR) to compare the non–cancerspecific mortality between HCC and non-HCC recipients
and explain the shape of the HR for HCC over time estimated by the FPM.18 By categorizing causes of death into
cancer and non–cancer-specific, if one assumes that the
increase in the hazard of post-LT mortality observed in
the HCC recipients is due to HCC occurrence, then it is
expected that the non–cancer-specific subdistribution hazard is similar in HCC and non-HCC recipients. A timevarying coefficient for HCC was used to investigate the
proportionality of subdistribution hazards.

Missing Data
The percentage of missing records for most covariates
was low, with organ appearance having the highest at
10.6%. Kaplan–Meier survival curves and log-rank tests
were used to investigate whether missingness (in any variable) was associated with survival. Of the 9586 eligible
recipients, 6724 patients (70.2%) had complete data for all
covariates. Survival curves for complete and noncomplete
cases were not significantly different (P = 0.334). The distributions of each variable were also similar for complete
and noncomplete cases. Therefore, there was little evidence
of a systematic difference between the two groups, justifying a complete-case analysis.19 Descriptive analysis was
carried out using the full data (Tables S4 and S5, SDC,
http://links.lww.com/TP/C507) and multivariable models
using the complete cases.
All statistical analysis was completed in Stata version
15.20 This study obtained Health Research Authority
(HRA) Research Ethics approval (17.LO.0231) and HRA
CAG approval (17/CAG/0025).
RESULTS
Donor and Recipient Characteristics

Of the 9586 eligible recipients, 1885 were transplanted for HCC. Donor and recipient characteristics differed between HCC and non-HCC recipients (Tables 1
and 2). On average, HCC recipients were older, more
likely to be male, of non-White ethnicities, and more

TABLE 2.

Mean (SD)
Median (range)
Male, n (%)
Female, n (%)
Mean (SD)
Median (range)
DBD, n (%)
DCD, n (%)
Identical, n (%)
Compatible, n (%)
Incompatible, n (%)
Whole, n (%)
Segment, n (%)
Healthy, n (%)
Abnormal, n (%)
Mean (SD)
Median (range)
Trauma, n (%)
CVA, n (%)
Other, n (%)

48.5 (15.5)
50 (12, 85)
1083 (57.5)
802 (42.5)
26.2 (4.7)
25.5 (14.3, 53.3)
1467 (77.8)
418 (22.2)
1830 (97.1)
53 (2.8)
2 (0.1)
1779 (94.4)
106 (5.6)
1205 (73.9)
426 (26.1)
9.1 (2.9)
8.8 (0.8, 21)
235 (12.5)
1201 (64.0)
442 (23.5)

HCC recipients (N = 1885)

46.5 (15.7)
48 (5, 86)
4044 (52.5)
3657 (47.5)
25.8 (4.8)
25.2 (10.5, 67.6)
6781 (88.1)
920 (11.9)
7481 (97.2)
203 (2.6)
16 (0.2)
7115 (92.4)
586 (7.6)
5441 (78.4)
1498 (21.6)
9.7 (3.0)
9.5 (0, 23)
1011 (13.2)
5083 (66.2)
1579 (20.6)

Non-HCC recipients
(N = 7701)

BMI, body mass index; CIT, cold ischemia time; CVA, cerebrovascular accident; DBD, donation after brain death; DCD, donation after circulatory death; HCC, hepatocellular carcinoma; LT, liver transplantation.

Cause of death

CIT, hours

Organ appearance

Graft type

Donor versus recipient blood group match

Donor type

BMI, kg/m2

Sex

Age at donation, y

Variable

0.019

<0.001

<0.001

0.003

0.688

<0.001

<0.001

<0.001

<0.001

P
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likely to have tested positive for HCV antibodies before
LT (Table 1).
Despite HCC recipients being older, they tended to be in
better overall health than non-HCC recipients (Table 1).
They were physically more active, had a lower median
United Kingdom End-Stage Liver Disease score, were
less likely to have symptoms of end-stage liver disease
(encephalopathy, variceal bleeding, and ascites), and were
less likely to require ventilation, renal support, or have
had previous abdominal surgery. However, HCC recipients
were more likely to receive poorer quality livers, including
those documented as having an abnormal appearance.
Nonparametric Survival Analysis

Recipients were followed for up to 20.3 y post-LT.
Median time to death was 3.0 y in recipients who died‚
and median time to censoring was 4.8 y in those who were
alive at their last examination before data extraction. For
HCC recipients, these figures were 2.2 y and 3.8 y, and for
non-HCC recipients, they were 3.3 y and 5.0 y, respectively.
For HCC recipients, unadjusted Kaplan–Meier survival estimates at 6 mo, 5 y‚ and 10 y were 93.0% (95%
confidence interval [CI], 91.8%-94.1%), 71.7% (95%
CI, 69.2%-74.0%), and 57.2% (95% CI, 53.8%-60.3%),
respectively. These figures for non-HCC recipients were
92.2% (95% CI, 91.6%-92.8%), 79.8% (95% CI, 78.8%80.8%), and 66.4% (95% CI, 65.0%-67.7%). Kaplan–
Meier survival curves (Figure 2) showed that short-term
survival was superior in HCC recipients up to approximately 8 mo compared with non-HCC recipients, with
HCC recipients experiencing worse outcomes thereafter.
The 95% CI for non-HCC estimates was narrow over
the whole follow-up period‚ whereas the 95% CI for
HCC estimates widened with time, reflecting the lack of
recipient deaths after 15 y in this group. There was strong

7

evidence of a difference between the survival curves (P <
0.001) (Figure 2).
Multivariable Cox Proportional Hazards Model

Adjusting for confounders, and assuming proportional
hazards, the estimated HR for HCC relative to non-HCC
was 1.27 (95% CI, 1.11-1.45; P < 0.001). A Schoenfeld
test and residuals showed evidence against the proportional hazards assumption for HCC (P = 0.044). All other
covariates were modeled as constant over time. No interactions were significant at the 5% level.
Stratified and Cox predicted survival curves at the baseline values of covariates by HCC diagnosis are shown in
Figure 3. The Cox proportional hazards model predicted
lower survival estimates in HCC recipients (light blue curve)
compared with non-HCC recipients within the first year
after LT, whereas the stratified survival estimates showed
better survival for HCC recipients (dark blue curve). Thus,
the Cox proportional hazards assumption does not accurately model short-term survival patterns by HCC.
Flexible Parametric Model

Figure 4 shows the adjusted HR and 95% CI for HCC
over time after LT estimated from the FPM. The estimated
hazard of death in HCC recipients was significantly lower
than that in non-HCC recipients until the first month
after LT (HR = 0.76; 95% CI, 0.59-0.99; P = 0.044). The
HR then increased sharply to its maximum, observed at
approximately 1.3 y (HR = 2.07, 95% CI, 1.70-2.52;
P < 0.001), before decreasing. The HR crossed one at
around 2 mo and 12.4 y after LT, so the hazards for allcause mortality in HCC and non-HCC recipients were estimated to be identical at these times. There was evidence at
the 5% level of an increased risk of death for HCC recipients compared with non-HCC recipients between 4 mo

FIGURE 2. Unadjusted Kaplan–Meier estimates of survival after liver transplantation by HCC diagnosis. HCC, hepatocellular carcinoma.
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FIGURE 3. Stratified and Cox predicted survival estimates after liver transplantation by HCC diagnosis. HCC, hepatocellular carcinoma.

FIGURE 4. Adjusted time-varying HR for hepatocellular carcinoma recipients relative to non-HCC recipients after liver transplantation
was estimated using the flexible parametric model. CI, confidence interval; HR, hazard ratio.

and 7.4 y (ie., the lower limit of the 95% CI was above 1).
Estimated HRs for confounding variables, adjusting for the
time-varying effect of HCC are in Table S6, SDC, http://
links.lww.com/TP/C507. Because proportional hazards
were assumed for confounders, their estimated HRs were
very similar in the FPM and the Cox proportional hazards
model (Table S7, SDC, http://links.lww.com/TP/C507).
Unlike the proportional hazards model (Figure 3),
there was a very close agreement between the stratified

and FPM predicted survival curves by HCC diagnosis
(Figure 5).
Figure 6 shows the adjusted HR and 95% CI for HCC
at different transplant years from the FPM with a time-varying interaction between HCC and transplant year. There
are no marked differences in the association between HCC
and the post-LT hazard of death, based on model extrapolations of the data. A test showed that this interaction was
not significant at the 5% level (P = 0.231). The 95% CIs

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc
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FIGURE 5. Stratified and FPM predicted survival estimates after liver transplantation by HCC diagnosis. FPM, flexible parametric
model; HCC, hepatocellular carcinoma.

FIGURE 6. Adjusted time-varying HR for hepatocellular carcinoma recipients relative to non–hepatocellular carcinoma recipients after
liver transplantation estimated from the flexible parametric model with a time-varying interaction between hepatocellular carcinoma
diagnosis and transplant year. HR, hazard ratio.

widened with transplant year due to fewer events observed
later in follow-up.
Competing Risks Analysis

Cause-specific Deaths in HCC and Non-HCC
Recipients
Of the 566 HCC recipient deaths, 90 (15.9%) were due
to HCC, 105 (18.6%) to other cancers, and 371 (65.5%)

to noncancer. Of the 2146 non-HCC recipient deaths, 333
(15.5%) were due to other cancers and 1813 (84.5%)
to noncancer. Distributions of event times were highly
right-skewed; half of the deaths caused by post-LT HCC
occurred within the first 1.8 y after LT, with the last such
death observed at 14.4 y.
Figure 7 shows that the unadjusted cumulative incidence for noncancer mortality was similar in HCC and
non-HCC recipients, possibly due to cohort selection and

10
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FIGURE 7. Cause-specific unadjusted cumulative incidence functions estimated in HCC (solid lines) and non-HCC (dashed lines)
recipients after liver transplantation. HCC, hepatocellular carcinoma.

the frailty of patients in both groups, and for other cancers, only slightly higher in HCC recipients. It also shows
that for HCC recipients, the unadjusted cumulative incidence for HCC mortality (solid green curve) was higher
than that for other cancers (solid blue curve) between 2 and
6 y after LT. From 6 y onwards, the unadjusted cumulative
incidence for other cancers mortality in the HCC recipients was higher. These results suggest that the increased
hazard of post-LT mortality observed in HCC recipients is
likely due to HCC occurrence.

Extending this model by adding a time-varying interaction
between HCC and transplant year showed no marked differences in the association between HCC and the post-LT
hazard of death for different years of follow-up.
In further analysis, a subdistribution hazard model
showed that non–cancer-specific mortality was not significantly different between HCC and non-HCC recipients,
implying that post-LT HCC occurrence was likely to be
the overriding cause of the increased hazard of death for
HCC recipients between 4 mo and 7.4 y after LT.

Subdistribution Hazard Model for Non–cancer-specific
Mortality

Comparison With Other Studies

After adjustment for confounding, there was no evidence of a time-varying effect of HCC on the incidence of
noncancer specific mortality (P = 0.735) and no evidence
of a difference in the incidence of noncancer specific mortality between HCC and non-HCC recipients (SHR = 0.94;
95% CI, 0.80-1.09; P = 0.390).
DISCUSSION
Summary of Results

Using data on over 9586 recipients from the UKLTR, a
time-varying comparison of post-LT all-cause mortality
between recipients with and without HCC was subject to
detailed survival analysis. Results from the Cox proportional
hazards model were of limited value as associations between
HCC and post-LT hazards of mortality varied over time.
Results from the FPM, which allowed for non–proportional hazards between HCC and non-HCC recipients,
showed that the hazard was significantly lower in HCC
recipients than in non-HCC recipients for the first month
after LT. After that, the estimated HR for HCC increased to
a maximum at around 1.3 y, at which the hazard for mortality was approximately twice that of non-HCC recipients.

To the authors’ knowledge, this is the first article in LT
literature to assess the smoothed time-varying association
between HCC and survival. Previously, Wallace et al considered a similar clinical question but used a simpler method
that involved using clinical criteria to split follow-up time
into discrete periods before applying Cox proportional
hazards models.8 This assumed constant relative hazards
within each time period and discrete jumps between them,
both of which may not be realistic.8,21 Unlike previous
studies, this one determines the post-LT time points at
which HCC has a protective effect before changing to a
detrimental effect on the post-LT hazard of death.
Explanation of Results

This analysis identifies that HCC recipients were more
likely to receive suboptimal donor organs with characteristics that were proven to have poorer post-LT outcomes.
This included livers that were either abnormal in appearance or from donors that were older, male, or DCD. In the
UK, the donor liver index was introduced to measure the
quality of donor’s livers, based on several donor factors
that were adjusted for in the models (eg, donor age, sex,
type, and whether the liver was split).22 However, adjustment for these donor factors, in addition to adjustment
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for recipient factors, did not drastically change the HR for
HCC.8 This supports the conclusion from this study that
post-LT HCC occurrence was primarily responsible for the
higher relative hazard of death in HCC recipients, rather
than the donor characteristics. The use of more marginal
donors in HCC patients reflects the relative urgency to
provide LT before their tumor progresses beyond transplantable criteria.8
These results also demonstrate that outcomes in patients
transplanted for HCC are worse than in those transplanted
for non-HCC indications, with a significantly higher hazard of death between 4 mo and 7.4 y. This is most likely
explained by post-LT HCC occurrence, and it must be
acknowledged that even with the adoption of the Milan
criteria, a significant proportion of HCC patients who are
at risk of tumor recurrence are still being selected for LT.
In half of these recipients, death from HCC is occurring
within 2 y post-LT.
Methodological Implications

FPMs have several advantages‚ and their use should
be encouraged in future analyses of follow-up studies of
transplant patients. With more precise long-term predictions of postoperative survival for HCC, the FPM could be
applied to a wide range of other donor and recipient risk
factors for survival after LT.
There are four main limitations of this study. First,
organ appearance is a subjective measure of organ quality, determined by surgeons who visually inspect the
liver at the time of retrieval. Though measurement bias
may be introduced, organ appearance remains a robust
prognostic marker of survival. The second limitation is
that multiple imputations (MIs) could have been used to
handle missing covariate values. However, there was little
evidence of systematic differences in survival and distributions of covariates between complete and noncomplete
cases. A complete-case analysis was deemed suitable for
giving unbiased estimates without a large loss in efficiency. It is unlikely that conclusions would have been
affected if MI had been used.23 Third, despite rigorous
risk adjustment, the potential for residual confounding
remains in all observational studies. Fourth, the study
did not have access to clinical data on baseline tumor
characteristics and explant pathology. Hence, it was not
possible to directly study which HCC patients have an
increased risk of recurrence and require closer post-LT
surveillance.
Clinical Implications

This study highlights two key clinical implications. The
first is that HCC patients are being listed and transplanted
at a stage beyond what is recommended for LT to be beneficial. In this context, early post-LT HCC is no recurrence at all but the undiagnosed extra-hepatic spread of
original cancer at the time of LT. A better understanding
of tumor biology (beyond the use of surrogate markers)
and the ability to detect circulating extra-hepatic tumor
cells could improve patient selection by identifying those
who would not be best served by LT. The use of preoperative biopsy and assessment of tumor differentiation,
as adopted by the Toronto criteria, may need to be given
more consideration.24
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The second implication is that post-LT surveillance of
HCC recipients should start early and continue for many
years to detect HCC recurrence. In this analysis, the first
post-LT HCC death was observed at around 1.2 mo.
Consistent practice of surveillance protocols ensures that
measures—including adjuvant HCC-directed therapies
(Sorafenib, locoregional therapies, liver resection)—to
reduce mortality in patients whose cancer has recurred are
not delayed.25
Currently, there is no defined protocol for post-LT surveillance of HCC in the UK and very little research conducted in this area. Due to the lack of standardization,
transplant center protocols vary. In the United States,
there is a 6-mo mandatory waiting period for LT in HCC
patients, allowing for continuous monitoring and avoiding
LT in patients whose cancer is likely to recur. This does
not happen in the UK as many HCC patients are transplanted earlier using DCD organs. Also, many studies have
developed risk scores to predict post-LT survival in these
patients (eg, based on alpha-fetoprotein trends, history of
locoregional therapy, etc) that could be extended to UK
populations.26,27
Using the results from this analysis to help create a targeted surveillance program in the UK could reduce the
number of outpatient appointments and improve accuracy in prognostication. This is important as it can benefit
patient counseling because discussions of prognosis may
be more optimistic if an HCC patient has survived the
period of the highest relative hazard of death.
CONCLUSION
The post-LT hazard of death in HCC patients is significantly higher than in non-HCC patients between 4 mo
and 7 y, which has implications for patient selection, organ
allocation, and optimal post-LT surveillance protocols.
FPMs can be more widely used to provide time-varying
comparisons of post-LT hazards for other donor and recipient characteristics.
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